Stock OJU1 ORAMED PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Oramed Pharmaceuticals Inc. Deutsche Boerse AG

Equities

OJU1

US68403P2039

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG
Other stock markets
 11:44:15 25/06/2024 am IST 		5-day change 1st Jan Change
2.017 EUR +0.50% Intraday chart for Oramed Pharmaceuticals Inc. -1.18% -3.54%
12/06 Scilex Holding Signs Commitment Letter for $100 Million Financing; Shares Advance Premarket MT
10/06 Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Chief Financial Officer, Effective as of June 18, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 89.6 110.4 543.9 470.6 93.18 91.01 -
Enterprise Value (EV) 1 89.6 110.4 543.9 470.6 93.18 91.01 91.01
P/E ratio -6.28 x -7.57 x -46.1 x -12.8 x 16.5 x -224 x -6.79 x
Yield - - - - - - -
Capitalization / Revenue 33.1 x 40.8 x 602 x 174 x 69.5 x 121 x 45.5 x
EV / Revenue 33.1 x 40.8 x 602 x 174 x 69.5 x 121 x 45.5 x
EV / EBITDA - - - - - - -
EV / FCF - -88,20,227 x - - - - -
FCF Yield - -0% - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 17,398 26,049 38,086 39,115 40,339 40,629 -
Reference price 2 5.150 4.240 14.28 12.03 2.310 2.240 2.240
Announcement Date 27/11/19 24/11/20 30/03/22 06/03/23 06/03/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 2.703 2.71 0.904 2.703 1.34 0.75 2
EBITDA - - - - - - -
EBIT 1 -14.63 -11.76 - -40.6 -15.77 -15.63 -26
Operating Margin -541.29% -433.84% - -1,501.96% -1,176.79% -2,084.13% -1,300%
Earnings before Tax (EBT) 1 -14.06 -11.51 - -37.66 5.088 -0.383 -14.5
Net income 1 -14.36 -11.51 - -36.56 5.525 -0.383 -14.5
Net margin -531.08% -424.76% - -1,352.61% 412.31% -51.07% -725%
EPS 2 -0.8200 -0.5600 -0.3100 -0.9400 0.1400 -0.0100 -0.3300
Free Cash Flow - -12.52 - - - - -
FCF margin - -462.07% - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 27/11/19 24/11/20 30/03/22 06/03/23 06/03/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 0.666 0.674 0.682 0.681 0.666 0.674 - - - 0.25 0.25 0.25
EBITDA - - - - - - - - - - - -
EBIT 1 -11.25 -11.42 -8.189 -9.74 -5.208 -3.791 -2.893 -3.877 - -3.4 -3.7 -5.6
Operating Margin -1,689.49% -1,693.92% -1,200.73% -1,430.25% -781.98% -562.46% - - - -1,360% -1,480% -2,240%
Earnings before Tax (EBT) 1 -10.71 -11.07 -7.153 -8.736 -3.611 -1.313 -3.284 13.3 - 0.4 -0.05 -2.3
Net income 1 -10.42 -10.53 -7.06 -8.543 -3.395 -1.194 -3.222 13.34 1.536 0.4 -0.05 -2.3
Net margin -1,565.32% -1,562.76% -1,035.19% -1,254.48% -509.76% -177.15% - - - 160% -20% -920%
EPS 2 -0.2700 -0.2700 -0.1800 -0.2200 -0.0800 -0.0300 -0.0800 0.3300 0.0400 0.0100 - -0.0600
Dividend per Share - - - - - - - - - - - -
Announcement Date 12/05/22 10/08/22 10/11/22 06/03/23 11/05/23 10/08/23 09/11/23 06/03/24 09/05/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - -12.5 - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 0.02 - - - - - -
Capex / Sales 0.55% - - - - - -
Announcement Date 27/11/19 24/11/20 30/03/22 06/03/23 06/03/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Oramed Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.23 USD
Average target price
3.25 USD
Spread / Average Target
+45.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+38.36% 5.25TCr
LONZA GROUP AG Stock Lonza Group AG
+36.73% 3.93TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.63% 3.9TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+25.46% 2.82TCr
CELLTRION, INC. Stock Celltrion, Inc.
-11.17% 2.66TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.44% 2.62TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.09% 1.42TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.93% 1.26TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-5.30% 1.17TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ORMP Stock
  4. OJU1 Stock
  5. Financials Oramed Pharmaceuticals Inc.